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Conventional radiation therapy directs photons (X-rays) and electrons at tumours with the intent of eradicating the neoplastic tissue
while preserving adjacent normal tissue. Radiation-induced damage to healthy tissue and second malignancies are always a concern,
however, when administering radiation. Proton beam radiotherapy, one form of charged particle therapy, allows for excellent dose
distributions, with the added benefit of no exit dose. These characteristics make this form of radiotherapy an excellent choice for the
treatment of tumours located next to critical structures such as the spinal cord, eyes, and brain, as well as for paediatric malignancies.
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Conventional radiation therapy, which utilises photon (X-ray)
beams, is frequently used in the locoregional treatment of cancer.
Tumour control is achieved by radiation-induced damage to DNA,
which ultimately causes tumour cell death. In vitro, even the most
radioresistant cancers can be eliminated. In vivo, however, lethal
tumour doses are not always achievable because of radiation-
induced morbidity in normal tissues.
Radiation is currently delivered with substantially more preci-
sion than in the past because of advances in imaging and treatment
planning. To date, the most advanced photon beam delivery
method is intensity-modulated (IM) radiation therapy (IMRT),
which can deliver higher doses of radiotherapy to tumour targets
while reducing the dose delivered to selected normal tissues. With
IMRT, high doses to these selected normal tissues can be avoided
by applying numerous radiation fields of varying intensities from
different directions. But this requires increasing the volume of
normal tissue that is irradiated (i.e. a higher integral dose); hence,
one of the concerns of IMRT is that, over time, this exposure of
more tissue to low-dose radiation will cause a second malignancy
or other unwanted late normal tissue effect. This is especially
concerning with regards to paediatric patients receiving IMRT
(Miralbell et al, 2002). If these children are cured of their primary
cancer, they should have a relatively long lifespan, during which
time they may manifest a radiation-induced malignancy. Of
course, the risk of second malignancy is also a risk in adults, but
the fact that the median age of adult cancer patients at diagnosis is
in the seventh decade, that second malignancies after radiotherapy
are uncommon in adults, and that they usually manifest 10–15
years after treatment make them less of a concern. It is also worth
mentioning that intensity modulation using a scanned pencil beam
has also been applied to proton radiotherapy; dose distributions
are superior to those achievable with the more commonly
employed passively scattered proton beams (Weber et al, 2004),
and there is also less total body neutron dose from beam-shaping
devices (Miralbell et al, 2002).
Interest in the use of charged particle radiotherapy has been
primarily stimulated by the superior dose distributions – already
recognised by Wilson (1946) – compared to those produced by
photon therapy techniques. Protons, as do all charged particles,
have a very rapid energy loss in the last few millimeters of
penetration. This results in a sharply localised peak of dose, known
as the Bragg peak. The penetration depth of the Bragg peak is
directly related to the initial energy of the charged particle. The
Bragg peak, and hence desired dose, can thus be precisely placed
anywhere in the patient (see Figure 1). For irradiation of a tumour,
the proton beam energy and intensity are varied in order to
achieve the desired dose over the tumour volume. A single clinical
proton field, in contrast to a single photon field, can achieve dose
conformation to the target volume. In general, a set of proton fields
achieves significant dose reduction to uninvolved normal tissues
compared to a matched set of photon fields. Passively scattered
proton fields have a slightly higher entrance dose at the skin
(B75%) compared to megavoltage photon beams (B60%); more
than one port may be required with protons if adequate skin
sparing is to be achieved in patients being treated to high doses
with only protons.
Protons have comparable biologic effects in tissue relative to
high-energy X-rays used in conventional radiation therapy.
Evidence of this comes from the fact that the relative biological
effectiveness (RBE) of protons is approximately 1.1 (Paganetti
et al, 2002). The RBE of a proton beam is the ratio of the dose
required to produce a specified effect using a reference radiation,
usually
60Co photons, to the dose required to produce the same
effect. A generic RBE factor of 1.1 has been used at the Harvard
Cyclotron, Northeast Proton Therapy Center, Loma Linda
University, Paul Scherrer Institute in Switzerland, Orsay in France,
and Faure in South Africa, while Tsukuba in Japan and Uppsala in
Sweden have used 1.0. It is important to contrast these biologic
and physical properties of protons with those of neutrons and
heavier charged particles. Fast neutrons have a higher RBE in
tumour cells, but lack the physical dose advantages of charged
particles; the latter proved disadvantageous in the clinic
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www.bjcancer.com(Wambersie and Menzel, 1996). Heavier charged particles like
carbon ions combine a higher RBE with an improved physical dose
distribution; they may offer additional advantages for hypoxic and
other radioresistant tumours and clinical studies are in progress at
NIRS in Japan (Kamada et al, 2002; Tsujii et al, 2004) and GSI in
Germany (Schulz-Ertner et al, 2004). Many clinical studies with
protons have employed a combination of photons and protons; the
combination is facilitated by the similar biologic effects.
PROTON BEAM RADIOTHERAPY
The majority of patients receiving charged particle therapy have
been treated with protons. As of July 2004, over 39000 patients
have received part or all of their radiation therapy (RT) by proton
beams (Sisterson, 2004). Table 1 lists the currently operational
proton beam treatment facilities worldwide.
Initially, patients were being treated at facilities designed and
constructed for basic high-energy physics research, often resulting
in very cumbersome treatments, as the proton beams were limited
to a fixed (often horizontal) position, which meant that the patient
had to be moved to align the tumour on the trajectory of the beam.
This technique was in contrast to the isocentric capabilities of the
modern linear accelerator that rotates around a point in space and
can effectively target any site in the body. In addition, for many of
the proton machines, the energy of the beam (which defined the
depth of the Bragg peak) was only sufficient to treat superficial
lesions (such as those of the eye) or intermediate-depth lesions
(such as the base of skull). Owing to these technical factors and the
interests of the involved physicians, the clinical sites that had
initially received the most attention were uveal melanomas in the
eye and base of skull sarcomas. The major emphasis for proton
therapy clinical research initially was dose escalation for tumours
adjacent to critical normal structures that constrained the doses
that could be given with photons and for which local tumour
control with conventional radiotherapy was thus poor. One of the
pioneers in proton radiation therapy was the research facility at
the Harvard Cyclotron Laboratory (HCL) in Cambridge, Massa-
chusetts, operating in conjunction with the Massachusetts General
Hospital. Patient treatment commenced in 1961 and ended in 2002,
after the clinical programme was transferred to the Northeast
Proton Therapy Center at Massachusetts General Hospital. In total,
9116 patients were treated at the HCL.
The development of hospital-based cyclotrons with higher
energy beams capable of reaching deep-seated tumours (up to
B30cm), field sizes comparable to linear accelerators, and
rotational gantries have greatly facilitated proton radiation
therapy. The first of these hospital-based facilities opened at
Loma Linda University in California in 1990. Increasingly, there is
interest in protocols aimed at morbidity reduction in those tumour
sites in which tumour control with photons is good, such as many
paediatric tumours.
OCULAR (UVEAL) MELANOMA
Uveal melanoma is the most common primary ocular tumour.
Episcleral radioactive plaques and proton beam radiation are
alternatives to enucleation with the intent of preservation of sight.
The latter is not always achievable due to the proximity of the
cornea, lens, retina, fovea, or optic nerve. Typically, a total of 70
Cobalt Gray Equivalent (CGE) (1CGE represents the physical dose
of protons multiplied by an RBE factor and should thus have
similar biologic effects in the system of interest as 1 Gray (Gy) of
photon dose) is administered over five treatment sessions.
As of December 2002, over 3000 patients with uveal melanoma
had been treated with protons at the MGH in collaboration with





















Figure 1 Depth–dose distributions for a spread-out Bragg peak (SOBP,
red), its constituent pristine Bragg peaks (blue), and a 10MV photon beam
(black). The SOBP dose distribution is created by adding the contributions
of individually modulated pristine Bragg peaks. The penetration depth, or
range, measured as the depth of the distal 90% of plateau dose, of the
SOBP dose distribution is determined by the range of the most distal
pristine peak (labeled ‘Pristine peak’). The modulation width, measured as
the distance between the proximal and distal 90% of plateau dose values,
of the SOBP dose distribution is controlled by varying the number and
intensity of pristine Bragg peaks that are added, relative to the most distal
pristine peak, to form the SOBP. The dashed lines (black) indicate the
clinical acceptable variation in the plateau dose of 72%. The dot–dashed
lines (green) indicate the 90% dose and spatial, range and modulation
width, intervals. The SOBP dose distribution of even a single field can
provide complete target volume coverage in depth and lateral dimensions,
in sharp contrast to a single photon dose distribution; only a composite set
of photon fields can deliver a clinical target dose distribution. Note the
absence of dose beyond the distal fall-off edge of the SOBP.










ITEP, Moscow Russia 1969 3748 June-04
St Petersburg Russia 1975 1145 April-04
Chiba Japan 1979 145 Apr-02
PSI Switzerland 1984 4066 June-04
Dubna Russia 1999 191 Nov-03
Uppsala Sweden 1989 418 Jan-04
Clatterbridge England 1989 1287 Dec-03
Loma Linda California, USA 1990 9282 July-04
Nice France 1991 2555 April-04
Orsay France 1991 2805 Dec-03
iThemba LABS South Africa 1993 446 Dec-03
UCSF – CNL California, USA 1994 632 June-04
TRIUMF Canada 1995 89 Dec-03
PSI Switzerland 1996 166 Dec-03
HMI, Berlin Germany 1998 437 Dec-03
NCC, Kashiwa Japan 1998 270 June-04
HIBMC, Hyogo Japan 2001 359 June-04
PMRC, Tsukuba Japan 2001 492 July 04
NPTC, MGH Massachusetts, USA 2001 800 July-04
INFN-LNS, Catania Italy 2002 77 June-04
WERC Japan 2002 14 Dec-03
Shizuoka Japan 2003 69 July-04
MPRI Indiana, USA 2004 21 July-04
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The probability of eye retention at 5 years was estimated to be 90%
for the entire group and 97, 93, and 78% for patients with small,
intermediate, and large tumours, respectively.
Egger et al (2003) recently reported long-term results of eye
retention after treatment of uveal melanoma with proton beam
therapy. A total of 2645 patients were treated at Paul Scherrer
Institute in Switzerland, between 1984 and 1999. The overall eye
retention rates at 5, 10, and 15 years after treatment were 89, 86,
and 83%, respectively.
SARCOMAS OF THE SKULL BASE AND SPINE
Treatment of patients with sarcoma of the skull base is very
challenging because of the proximity of critical structures, notably,
the brain, brainstem, cervical cord, optic nerves, and optic chiasm.
Accordingly, surgery and conventional photon therapy has not
been very successful at controlling these tumours. Owing
to the necessity to deliver dose in a precise manner, the use of
proton therapy is becoming the treatment of choice for these
tumours.
At the Harvard Cyclotron (HCL), MGH physicians used a
combination of protons and photons to treat patients with
tumours of the skull base and cervical spine (Munzenrider and
Liebsch, 1999). A total of 169 patients with chordoma and 165
patients with chondrosarcoma were treated. Local control
(10-year) for skull base tumours was highest for chondrosarcomas,
intermediate for male chordomas, and lowest for female chordo-
mas (94, 65, and 42%, respectively). For cervical spine tumours,
10-year local control rates were not significantly different for
chordomas and chondrosarcomas (54 and 48%, respectively),
nor was there any significant difference in local control between
males and females. Actuarial rates (5-year) of endocrinopathy in
patients with base of skull lesions were as follows: 72% for
hyperprolactinaemia, 30% for hypothyroidism, 29% for hypogo-
nadism, 19% for hypoadrenalism, and no incidence of diabetes
insipidus (Pai et al, 2001), reflective of the proximity of the
pituitary to the sarcoma.
Treatment of spinal and paraspinal tumours is complicated by
the proximity of the spinal cord. Radiation tolerance of the spinal
cord is generally quoted at 45Gy, well below that necessary to
reliably control most sarcomas, which require doses of approxi-
mately 60Gy for subclinical microscopic disease, 66Gy for
microscopically positive margins, and in excess of 70Gy for gross
residual disease. Proton radiotherapy, with its ability to spare
adjacent tissues, offers advantages for treatment of tumours in this
location. Hug et al (1995) presented results on combined photon/
proton treatment of 47 patients with osteo- and chondrogenic
tumours of the axial skeleton. Actuarial local control (5-year) and
survival for patients with chondrosarcoma were 100 and 100%, and
with chordoma were 53 and 50%. Actuarial 5-year local control for
patients with osteosarcoma was 59%.
BENIGN MENINGIOMA
Complete surgical resection of meningiomas is difficult to achieve
in selected locations such as the sphenoid ridge, parasellar area,
and posterior fossa. Likewise, radiation therapy for these
intracranial tumours is complicated by the proximity of critical
neural structures, such as the visual pathways or the brain stem.
Proton beam radiation, with its high degree of conformality,
therefore would seem to be an attractive treatment modality.
Between 1981 and 1996, 46 patients with partially resected,
biopsied, or recurrent benign meningiomas were treated with
combined proton/photon radiation at the HCL/MGH (Wenkel
et al, 2000). The median dose to the tumour was 59CGE. Overall
survivals at 5 and 10 years were 93 and 77%, respectively, and the
recurrence-free rates at 5 and 10 years were 100 and 88%,
respectively. Three patients presented with local tumour recur-
rence at 61, 95, and 125 months. One patient died of focal brain
necrosis at 22 months. Neurologic complications, including
memory deficits and hearing loss, were also seen. Four patients
developed ophthalmologic toxicity. In all of these cases maximum
dose to the optic structures was greater than 58CGE. Endocrine
abnormalities following treatment were also seen.
Investigators from Paul Scherrer Institute recently reported on
the treatment of 16 patients with recurrent, residual, or untreated
intracranial meningiomas (Weber et al, 2004). The median
prescribed dose was 56CGE (52–64) at 1.8–2CGE per fraction.
Cumulative 3-year local control, progression-free survival, and
overall survival were 91, 91, and 92%, respectively. No patient died
of recurrent meningioma. Radiographic follow-up (median, 34
months) revealed an objective response in three patients and stable
disease in 12 patients. Cumulative 3-year toxicity-free survival was
76%. No radiation-induced hypothalamic/pituitary dysfunction
was observed.
Encouraging data with stereotactic external beam radiotherapy
and IMRT, however, have also been reported (Uy et al, 2002; Zabel
et al, 2005) and comparative studies need to be conducted to assess
whether there is any demonstrable difference in tumour control or
complications between these techniques and proton radiotherapy.
PARANASAL SINUS, NASAL, AND
NASOPHARYNGEAL TUMOURS
Fitzek et al (2002) performed a prospective study incorporating
chemotherapy, surgery, and combined proton–photon radio-
therapy for treatment of malignant neuroendocrine tumours of
the sinonasal tract. In all, 19 patients with olfactory neuroblastoma
(ONB) or neuroendocrinecarcinoma (NEC) were treated with two
courses of cisplatin/etoposide chemotherapy, followed by high-
dose proton–photon radiotherapy to 69.2CGE using 1.6–1.8CGE
per fraction twice daily in a concomitant boost schedule. Two
further courses of chemotherapy were given to responders. The 5-
year survival rate was 74%. The 5-year local control rate of initial
treatment was 88%. Acute toxicity of chemotherapy was tolerable,
with no patient sustaining more than grade 3 haematologic
toxicity. One patient developed unilateral visual loss after the first
course of chemotherapy; otherwise, the precision of delivery of
radiation with stereotactic setup and protons resulted in visual
preservation in all patients. Four patients who were clinically intact
developed radiation-induced damage to the frontal or temporal
lobe by magnetic resonance imaging criteria. Two patients showed
soft tissue and/or bone necrosis, and one of these patients required
surgical repair of a cerebrospinal fluid leak. The authors concluded
that this was a successful treatment approach for these patients.
Thornton et al reported encouraging results with treatment of
paranasal sinus tumours with combined photon–proton radio-
therapy.
At the Loma Linda University in California, 16 patients with
recurrent nasopharyngeal carcinoma were treated with conformal
proton radiation (Lin et al, 1999). Patients had initially been
treated with photon therapy using doses of 50–70Gy. An
additional 59–70CGE was administered using conformal proton
radiation. With a mean follow-up of 23 months, 24-month
actuarial overall and local-regional progression-free survival rates
were both 50%. No central nervous system complications were
observed.
CARCINOMA OF THE PROSTATE
Photon beam radiation dose escalation was studied in a
randomised trial at the MD Anderson Cancer Center (Pollack
et al, 2000). For patients with a pretreatment PSA of more than
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 1, an increase in total dose from 70 to 78Gy
with conformal photons improved the biochemical disease-free
survival. A French trial in which patients were randomised to
receive either 70 or 80Gy with conformal photons reported no
statistical difference in acute toxicity between the two groups; they
noted, respectively, 6 and 2% acute grade 3 urinary and rectal
toxicities (Beckendorf et al, 2004). Intensity-modulated radiation
therapy has also been used for dose escalation to the prostate while
attempting to minimise toxicity by limiting radiation dose to the
bladder and rectum. Investigators at the Memorial Sloan Kettering
Cancer Center (Zelefsky et al, 2002) treated over 700 patients with
IMRT to a dose of at least 81Gy. Only 28% of patients experienced
grade 2 urinary symptoms and one patient experienced urinary
retention. Late grade 2 rectal bleeding was experienced by 1.5% of
patients and four patients required transfusion or laser cauterisa-
tion (grade 3). The 3-year actuarial PSA relapse-free survival rates
for favourable, intermediate, and unfavourable risk groups were
92, 86, and 81%, respectively.
Investigators at MGH completed a phase III trial comparing
67.2Gy of photons vs 75.6CGE using a conformal perineal proton
boost for patients with advanced prostate cancer (Shipley et al,
1995). From 1982 through 1992, 202 patients with T3–T4 prostate
cancer received 50.4Gy by four-field photons. Patients then
received either 25.2CGE with conformal protons or a 16.8Gy
photon boost. No differences between the two groups were found
in overall survival, total recurrence-free survival, or local
recurrence-free survival. The local recurrence-free survival at 7
years for patients with poorly differentiated (Gleason 9 and 10)
tumours, however, was 85% on the proton arm and 37% on the
photon arm. Grade 1 and 2 rectal bleeding was higher in the proton
arm (32 vs 12%), as was urethral stricture (19 vs 8%). In
conclusion, dose escalation to 75.6CGE by conformal proton boost
improved local recurrence-free survival in a subset of patients, but
also increased late low-grade radiation sequelae; no increase in
overall survival was seen in any subgroup.
Investigators at the Loma Linda University Medical Center used
proton beam radiotherapy to treat patients with localised prostate
cancer. Between 1991 and 1997, over 1200 patients received either
all or part of their treatment by proton radiation (Slater et al,
2004). With a median duration of follow-up, overall 5- and 8-year
actuarial biochemical disease-free survival rates were 75 and 73%,
respectively. Acute grade 3 gastrointestinal and genitourinary (GU)
toxicity was less than 1%. Late grade 3 GU toxicity was seen in 14
patients, with eight of them having urethral strictures. The
actuarial 5- and 10-year rates for freedom from grade 3 and 4
GU toxicity were both 99%.
MGH and Loma Linda subsequently conducted a phase III
randomised trial of radiation dose in patients with early-stage
prostate cancer (Zietman et al, 2004). Between 1996 and 1999, 393
patients with early-stage prostate cancer received a conformal
proton radiation boost of either 19.8 or 28.8 Gray equivalent
(GyE). Following the boost, all patients received 50.4Gy using 3-D
conformal photons to the prostate, seminal vesicles, and peripro-
static tissues. At a median follow-up of 4 years, the cumulative
incidence estimates of the 5-year local failure rate (using the
surrogate of a PSA 41ngml
 1 at 42 years after radiation were
52.4% for the 70.2GyE group and 32.8% for the 79.2GyE group
(Po0.001). The 5-year biochemical failure rates were 37.3% for the
conventional dose group and 19.1% for the high-dose group
(P¼0.00001). These differences were seen for patients with
low-risk disease (T1b-2a, PSA o10, Gleason p6), as well as
intermediate-risk tumours. The 5-year biochemical failure rate in
the low-risk group was 34.9% in the conventional dose arm vs only
17.2% in the high-dose arm (P¼0.002); the figures for inter-
mediate-risk patients were 39.5 vs 21.3% (P¼0.01). At follow-up to
date, there was no difference in the overall survival rates between
the treatment arms. Importantly, dose escalation was achieved
with protons, without any comparable increase in significant acute
or late radiation morbidity. Only 2% of patients receiving
conventional dose and 1.5% receiving high-dose radiation
experienced acute urinary or rectal morbidity of RTOG grade
X3. The respective proportions for those experiencing any grade 2
acute morbidity were 62 and 69%. So far only 1.5 and 0.5%,
respectively, have experienced late morbidity of RTOG grade X3.
It will be important to ultimately determine whether proton
radiotherapy offers any clinical advantages to patients with
prostate cancer compared to IM radiotherapy or (in appropriately
selected cases) brachytherapy. This will require randomised
clinical trials.
PAEDIATRIC MALIGNANCIES
Investigators in Switzerland looked at the potential influence of
improved dose distribution with proton beams compared to
conventional or IM X-ray beams on the incidence of treatment-
induced secondary cancers in children (Miralbell et al, 2002). This
model allowed estimation of absolute risks of secondary cancer for
each treatment plan based on dose–volume distributions for
nontarget organs. Proton beams reduced the expected incidence of
radiation-induced secondary cancers for a rhabdomyosarcoma
patient by a factor equal to or greater than 2, and for the
medulloblastoma cases a factor of 8–15 (because of the larger
target volume) when compared with either IM or conventional X-
ray plans. This study underscores the concern with using radiation
therapy in the treatment of paediatric malignancies. It is the goal of
clinicians not only to eradicate the primary tumour but also to
minimise the risk of radiation-induced malignancies over the
lifetime of these patients. It also underscores the fact that the
advantages for protons may be greater with larger rather than
smaller target volumes. Owing to technical limitations on field size
and depth imposed by some of the modified physic research
laboratory facilities employed for treatment in the past, some of
the most notable early clinical achievements with protons were
with small, superficial targets (i.e. ocular melanomas), leaving the
mistaken impression with some clinicians that the advantages for
protons were confined to small target volumes.
In a study performed by the MGH group, treatment plans
utilising standard photon therapy, IMRT, or protons for craniosp-
inal axis irradiation and posterior fossa boost were compared in a
patient with medulloblastoma (St Clair et al, 2004). Substantial
normal tissue sparing was realised with IMRT and proton
irradiation of the posterior fossa and spinal axis. The dose to
90% of the cochlea was reduced from 101% of the prescribed
posterior fossa boost dose from conventional X-rays to 33% with
IMRT and to 2% with protons. Dose to 50% of the heart volume
was reduced from 72% for photons to 30% for IMRT and to 0.5%
for protons. (The dose distribution for a child with medulloblas-
tomas undergoing craniospinal irradiation with protons is shown
in Figure 2.)
LLU investigators reported a reduction in acute toxicity with the
treatment of three children with medulloblastoma treated with
craniospinal irradiation using the proton beam technique (Yuh
et al, 2004). Loma Linda investigators also evaluated proton beam
irradiation in the treatment of paediatric patients with intracranial
low-grade astrocytoma (Hug et al, 2002a). Between 1991 and 1997,
27 patients underwent fractionated proton radiation therapy for
progression of recurrent low-grade astrocytoma. In all, 25 of the 27
patients (92%) were treated for progressive, unresectable, or
residual disease following subtotal resection. Mean target dose was
55.2CGE (50.4–63.0) and fraction size was 1.8CGE. At a mean
follow-up period of 3.3 years (0–6.8 years), six out of 27 patients
experienced local failure within the irradiated field and four out of
27 had died. Local control and survival were 87 and 93%,
respectively, for centrally located tumours, 71 and 86% for
hemispheric tumours, and 60 and 60% for tumours of the
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performance status, except one, who developed Moyamoya
disease. All six patients with optic pathway tumours and useful
vision maintained or improved their visual status.
Four paediatric patients presenting with aggressive giant cell
tumours of the skull base were treated with a combination of
proton and photon beam radiation at MGH (Hug et al, 2002b).
Combined proton and photon radiation therapy was based on 3-D
planning. Target doses of 57.6–61.2CGE were given in daily
fractions of 1.8CGE. With observation times between 3.1 and 5.8
years, all four patients were alive and well and remained locally
controlled without evidence of recurrent disease. Except for one
patient with partial pituitary insufficiency following radiotherapy
for recurrent sellar disease, no late effects attributable to radiation
therapy to date have been observed.
Protons offered a preferable dose distribution to photons in two
patients treated for orbital rhabdomyosarcoma (Hug et al, 2001).
Dose–volume histograms were obtained for target and nontarget
regions, including the lens, bony orbit, pituitary gland, optic
chiasm, optic nerves, lacrimal gland, and ipsilateral frontal and
temporal lobes. Doses to 90, 50, and 5% of lens volume were kept
at less than 1%, less than 2%, and less than 8%, respectively. At a
mean follow-up of 3 years, visual acuity for both patients was
excellent and there was no evidence of cataract formation.
Furthermore, pituitary function was normal; cosmetically, only
mild enopthalmos was noticeable. The steep dose gradient beyond
the orbit minimised irradiation of normal brain parenchyma, with
almost sparing of the pituitary gland.
Ongoing clinical trials of proton beam radiation therapy are in
progress at the Northeast Proton Therapy Center (MGH) for
paediatric patients with medulloblastoma, rhabdomyosarcoma,
other paediatric sarcomas, and retinoblastoma. Protons are also
used for treatment of paediatric malignancies at the Loma Linda
University Proton Center, and the groups at Orsay in Paris and
Paul Scherrer Institute are using proton radiotherapy for
paediatric tumours. Protons are also approved for use in patients
undergoing radiation therapy as part of treatment on Children’s
Oncology Group protocols.
OTHER TUMOURS
Encouraging results with proton beam radiotherapy have also been
reported for hepatocellular carcinoma (Chiba et al, 2005) and
medically inoperable, early-stage lung cancers (Bush et al, 2004).
CONCLUSIONS
As discussed, the main benefit of proton therapy over photon
beam radiotherapy is the absence of exit dose, which offers the
opportunity for highly conformal dose distributions, while
simultaneously irradiating less normal tissue. This technology
therefore reduces irradiation to normal tissue, while permitting
dose escalation to levels not achievable with standard techniques.
Dose escalation with protons has been shown in a randomised
clinical trial for prostate cancer to improve local tumour control;
clinical experience with proton radiotherapy in phase II studies in
other anatomic locations suggests that dose escalation in other
sites results in improved local control. With reduction of normal
tissue dose, proton therapy has been shown to allow for better
acute tolerance of combined chemotherapy and radiation therapy;
this has been reported for medulloblastoma (Yuh et al, 2004).
Ongoing clinical studies are expected to demonstrate similar gains
with other tumour types. Improvements in acute tolerance can be
expected to minimise interruptions in both chemotherapy and
radiotherapy in patients receiving combined modality treatment,
with the potential for simultaneous improvement in local and
systemic treatment. Equally important is the potential for a
decrease in the appearance of late normal tissue effects including
radiation-induced malignancies. The importance of this issue
cannot be overemphasised when considering the irradiation of
paediatric patients.
As noted above, there is also clinical interest in heavier ions,
carbon in particular, which have a similar finite range in tissue as
protons, a very sharp lateral penumbra, but also have a higher RBE
than protons. There is some encouraging preliminary experience
from the facility in Chiba and from GSI in Germany (Schulz-Ertner
et al, 2004; Tsujii et al, 2004). Further follow-up on these patients,
in particular for potential late effects with the higher RBE particles,
will be needed before their potential role with respect to protons
and IMRT photons can be fully assessed. Carbon ion facilities,
however, because of the 12-fold heavier mass of carbon ions
compared to protons, are currently more costly than proton
facilities, so that appropriate indications will need to be defined.
The expense of proton therapy per patient is expected to
decrease as more facilities are built and greater numbers of
patients are treated. Current estimates place the relative cost of
proton radiation therapy compared to IM photon beam radiation
therapy in the range of 2.4, but might come down to 1.7–2.1 over
the next 5 years (Goitein and Jermann, 2003). A recent publication
from Sweden actually projected lower health-care expenses using
proton beam radiotherapy when compared to conventional
radiation therapy in the treatment of a child with medulloblasto-
ma, because of the substantial health-care burden in managing the
late effects of conventional radiotherapy (Lundkvist et al, 2005).
At the present time, we believe that all paediatric patients should
be considered for referral, as well as all cases where the proximity
of tumour to critical structures prohibits the administration of
adequate radiation doses using photon techniques. Rapid advances
in photon radiotherapy with image-guided IMRT, stereotactic
radiotherapy, and brachytherpy are, however, competing technol-
ogies for adult patients and appropriate clinical studies will be
important to define the relative benefits and indications for these
different technologies.
Figure 2 Sagittal and coronal composite dose displays for a child with
high-risk medulloblastoma undergoing craniospinal irradiation with protons.
Prescription dose to the craniospinal axis for this child with high-risk disease
is 36CGE and the dose to the posterior fossa is 54CGE. Note the absence
of significant exit dose beyond the anterior border of the vertebral bodies,
thus sparing the bowel, heart, and mediastinum from potential side effects
of radiotherapy.
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